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ABSTRACT
As PI3K/Akt signaling is frequently deregulated in a wide variety of human 
tumors, PI3K inhibitors are an emerging class of drugs for cancer treatment. The 
monitoring of the drug behavior and distribution in the biological system can play an 
important role for targeted therapy and provide information regarding the response 
or resistance to available therapies. In this study, therefore, we have developed a 
family of xanthine derivatives, serving as a dual function exhibiting fluorescence, 
as well as inhibiting PI3K. Among them, HS-133 showed anti-proliferative effects 
and was monitored for its subcellular localization by a fluorescence microscopy.  
HS-133 suppressed the PI3K/Akt pathway and induced cell cycle arrest at the G0/G1 
phase. The induction of apoptosis by HS-133 was confirmed by the increases of the 
cleaved PARP, caspase-3, and caspase-8. Furthermore, HS-133 decreased the protein 
expression of HIF-1α and VEGF, as well inhibited the tube formation and migration of 
the human umbilical vein endothelial cells. In vivo imaging also showed that tumors 
were visualized fluorescent with HS-133, and its oral administration significantly 
inhibited the growth of tumor in SkBr3 mouse xenograft models. Thus, we suggest 
that HS-133 may be used as a fluorescent anticancer agent against human breast 
cancer.
INTRODUCTION
Phosphatidylinositol 3-kinases (PI3K) are 
responsible for the generation of 3-phosphorylated 
inositides, such as the important second messenger 
phosphatidylinositol-3, 4, 5-trisphosphate (PIP3), resulting 
in an activation of the signal transduction pathways 
implicated in many essential cellular processes, including 
metabolism, cell survival, growth, and differentiation 
[1–4]. The PI3K pathway is initiated by the binding of 
growth factors or insulin to the cell surface receptors, 
which activates the class IA PI3K that converts the plasma 
membrane lipid phosphatidylinositol-4, 5-bisphosphate 
(PIP2) to PIP3. PIP3 plays a key role in recruiting proteins, 
such as the serine/threonine kinases phosphoinositide-
dependent kinase 1 (PDK1) and Akt (also known as 
PKB), to the plasma membrane [3, 5]. This in turn 
activates Akt which subsequently phosphorylates mTOR 
and several other cytoplasmic proteins [6]. A serine/
threonine kinase, mTOR, has diverse cellular functions, 
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including regulation of mRNA translation, cell growth 
and proliferation, ribosome biogenesis, transcription, 
cytoskeletal reorganization, long-term potentiation and 
autophagy [7]. The mTOR serves as the catalytic subunit 
in two distinct complexes, mTOR complex 1 (mTORC1) 
and mTOR complex 2 (mTORC2), which vary both in 
their subunit components and their function [8, 9].
The PI3K/Akt signaling pathway is the most 
commonly activated pathway in human cancer [6, 10, 
11]. In particular, members of class IA PI3Ks among 
several isoforms of the PI3K family are implicated 
and often mutated in human cancer [12–15]. The 
deregulation of this pathway has been implicated in 
tumor initiation, cell growth and survival, invasion and 
angiogenesis [4]. As such, there is a strong rationale for 
targeting PI3K, especially in cancers that are known to 
carry alterations in PI3K/Akt signaling. Inhibition of 
this pathway is an attractive target for the development 
of new anticancer strategies. A new generation of PI3K 
inhibitors is emerging, overcoming earlier problems of 
poor selectivity, unfavorable pharmacokinetic profiles, and 
unacceptable toxicity [10, 16]. A number of these agents 
have entered the early phase clinical trials [17]. Some 
major pharmaceutical companies are currently testing the 
hypothesis that ATP competitive mTOR or dual-PI3K/
mTOR inhibitors will be able to overcome the limited 
clinical responses that have been observed with rapamycin 
and its analogs (rapalogs) [18].
The monitoring of the drug behavior and distribution 
in the biological system can play an important role for the 
targeted therapy and provide a biological rationale for the 
design of new therapeutics with improved properties and 
fewer side effects [19]. A response to PI3K inhibition is 
often associated with tumor stasis rather than shrinkage 
[20–23]. The utility of such traditional imaging methods 
as computed tomography (CT), ultrasound imaging, and 
magnetic resonance imaging (MRI) in monitoring early 
response is limited [23]. Accordingly, there is a critical 
need for noninvasive functional imaging biomarkers 
that confirm drug delivery and molecular drug activity. 
The tethering of fluorescent dyes to drugs is a popular 
method for visually monitoring the time course of the 
drug behavior, and also provides a useful tool for studying 
cellular, animal and clinical imaging in a noninvasive, 
nonradioactive, and stable procedure [24–26]. However, 
the addition of fluorophores into the drug molecules 
often causes undesired effects on the binding affinity, cell 
permeability, in vivo activity and toxicity. These problems 
can be overcome if one drug has a dual function that 
exhibits fluorescence as well as anticancer activity.
Xanthines are known as important alkaloids, which 
are biologically active and constitute a major class of 
adenosine receptor antagonists, as well as fluorophores. 
We recently reported on the identification of a family of 
potent fluorescent PI3Kα inhibitors from xanthine scaffold 
in which the part of the fluorophore was engineered to be 
a pharmacophore capable of inhibiting PI3Kα [26, 27]. 
Further we showed that the xanthine derivatives blocked 
cancer cell proliferation and monitored its subcellular 
localization by fluorescent microscopy [26].
In the study, we selected N-(4-(7-(3-Fluorophenyl)-1, 
3-dimethyl-2, 6-dioxo-2, 3, 6, 7-tetrahydro-1H-purin-8-yl)
phenyl) acetamide (HS-133), which was found to be the 
most potent fluorescent PI3K inhibitor and investigated 
whether or not HS-133 possesses anti-cancer activity 
against breast cancer and its molecular mechanism. 
HS-133 potently inhibited PI3K/Akt pathway signaling 
and cell growth/proliferation in human breast cancer cells 
together with suppressing tumor growth in the xenograft 
models. Furthermore, the inherent fluorescence of HS-133 
was detected in tumor bearing mice, as well as intracellular 
localization, and its pharmacokinetic properties exhibited 
good oral bioavailability.
RESULTS
Synthesis and binding mode of a new PI3Kα 
inhibitor, HS-133
A novel compound HS-133 was synthesized and 
was found to be a potent ATP-competitive inhibitor against 
PI3Kα (Fig. 1A) [26]. The calculated binding mode of 
the inhibitor HS-133 in the ATP-binding sites of PI3Kα 
was calculated using the modified Auto Dock program 
in Fig. 1B. Hydrogen bonding groups on the inhibitors 
appeared to point toward the backbone groups of the ATP 
binding site, with their hydrophobic groups situated in 
the proximity of the Gly loop. The carbonyl moiety at the 
3-position of xanthine core can forms a hydrogen bond 
to the backbone aminocarbonyl nitrogen of Val851 in the 
hinge region, and the amide group of HS-133 donates a 
hydrogen bond to the side-chain carboxylate of Asp810. In 
addition, the fluoro group at the 5-phenyl group appeared 
to form a hydrogen bond with the hydroxyl group of 
Ser774. These three hydrogen bonds appear to play a role 
of anchoring HS-133 at the ATP-binding site. Compound 
HS-133 can be further stabilized in the ATP-binding site 
of the PI3Kα via hydrophobic interactions with the side 
chains of Lys776, Asp805, Asp806, Asp806, Tyr836, 
Ile848, Asp933, and Gly935. Thus, the overall structural 
features derived from the docking simulations suggested 
that the inhibitory activity of HS-133 should stem from 
multiple hydrogen bonds and hydrophobic interactions 
established simultaneously in the ATP-binding site.
Intracellular monitoring studies by 
confocal microscopy
When SkBr3 breast cancer cells were incubated 
with HS-133 (10 μM) for 4 h, fluorescence became clearly 
visible in the cytoplasm of SkBr3 cells, providing visual 
evidence of the compound entering cells and information 
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on the intracellular distribution pattern (Fig. 1C). 
Furthermore, at 24 h after the treatment, fluorescence 
images of the cells revealed severe morphological changes 
such as shrinkage, elongation, or a disorder in cell shape 
(data not shown), suggesting that this approach can also 
be useful for monitoring the antiproliferative processes 
in cancer cells associated with drug retention and 
concentration as a function of time.
HS-133 blocks the PI3K/Akt pathway in breast 
cancer cells
It has been shown that breast tumor cell growth 
is closely related to the activation of the PI3K/Akt 
pathway [28–30]. The IC50 determination was performed 
using radiometric kinase assays ([γ-33P]-ATP) at the 
Reaction Biology Corp. (Malvern, PA), which revealed 
Figure 1: Chemical structure and characterization of HS-133. (A) Chemical structure of HS-133 [N-(4-(7-(3-fluorophenyl)-1,3-
dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl) phenyl) acetamide]. (B) Calculated binding mode of HS-133 in the ATP-binding site 
of PI3Kα. Carbon atoms of the protein and the ligand are indicated in cyan and magenta, respectively. Each dotted line indicates a hydrogen 
bond. (C) Confocal microscopic observation of the intracellular HS-133 (10 μM) disposition in SkBr3 cells.
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high potency against PI3Kα with an IC50 of 0.992 μM 
(Fig. 2A). Therefore, we evaluated the effects of HS-133 
on the PI3K/Akt pathway in breast cancer cells. The PI3K 
inhibitory activity of HS-133 was assessed in the SkBr3 
cells. The phosphorylation of Akt and its substrate, mTOR, 
and phosphorylation of downstream factors, including 
p70S6K and 4E-BP1were also effectively suppressed 
(Fig. 2B).
Figure 2: Effect of HS-133 on PI3K/Akt signaling pathway in SkBr3 cells. (A) The inhibitory activity of HS-133 against PI3Kα 
in vitro. (B) Western blotting analysis in SkBr3 cells treated with HS-133 at various doses (1–50 μM) for 6 h.
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HS-133 inhibits the growth of breast cancer cells
To determine whether HS-133 can function as a 
novel anticancer compound, we tested the ability of this 
compound to inhibit the growth of breast cancer cell lines 
(SkBr3, T47D, and MCF-7) using an MTT assay. The 
cells were exposed to various concentrations (0.5–50 μM) 
of HS-133 for 48 h. As shown in Fig. 3A-C, HS-133 
inhibited the growth of all three breast cancer cell lines 
in a dose-dependent manner. The IC50 values of HS-133 
were 46.76 μM for SkBr3, 9.4 μM for T47D, and 9.15 μM 
for MCF-7.
HS-133 induces cell cycle arrest at G0/G1 phase 
and apoptosis
To examine the relationship between the growth 
inhibitory effect of HS-133 and cell cycle progression, we 
analyzed cell cycle distribution of SkBr3 cells by HS-133 
Figure 3: Effect of HS-133 on the proliferation of human breast cancer cells. Inhibitory effect of HS-133 on cell proliferation 
in SkBr3 (A) T47D (B) and MCF-7 (C) Cell growth inhibition was assessed by MTT assay. Each value is the mean (±S.D.) from triplicate 
samples.
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using a flow cytometry. The SkBr3 cells were treated for 
24 h with various concentrations of HS-133 (1, 10, 50 μM) 
and collected and stained with PI and then analyzed by 
FACS. As shown in the Fig. 4A and 4B, HS-133 increased 
the number of cells in the G0/G1 phase. The up-regulation 
of p27, cyclin dependent kinase (CDK) inhibitor, is related 
to G0/G1 cell cycle arrest and contributes to the down-
regulation of cyclin D1 [31]. Thus, we evaluated the 
effect of HS-133 on the protein expressions of p27 and 
cyclin D1. HS-133 increased the expression of p27 while 
decreasing cyclin D1 expression (Fig. 4C).
Since PI3K and its downstream effectors appear to 
mediate anti-apoptotic signals, we examined the effect 
of HS-133 on apoptosis. As shown in Fig. 5A, HS-133 
promoted the cleavage of PARP, caspase-9, caspase-8 and 
casepase-3. We also observed that the levels of Bax, pro-
apoptotic protein, were increased by HS-133 treatment 
in a dose-dependent manner. Furthermore, induction of 
apoptosis by HS-133 was confirmed by visualizing the 
fragmented DNA with TUNEL staining (Fig. 5B). These 
results showed that HS-133 could induce apoptosis in the 
SkBr3 cells.
HS-133 suppresses angiogenesis
Since HIF-1α is the major regulator of cellular 
adaptive responses to hypoxia, we examined the effect of 
HS-133 on the expression of the HIF-1α in SkBr3 cells. 
The cells were treated with various concentrations of 
HS-133 (1–50 μM) under hypoxic mimicking conditions 
induced by a treatment with 100 μM CoCl2 for 16 h. As 
shown in Fig. 6A, HS-133 inhibited the hypoxia-induced 
HIF-1α expression. To further determine the effect of HS-
133 on hypoxia-induced VEGF, an immediate downstream 
target gene of HIF-1α, the protein and production of 
VEGF were measured by western blotting and ELISA in 
the SkBr3 cells. A notable increase of VEGF was observed 
under hypoxic conditions, and the HS-133 treatment was 
found to suppress the VEGF expression and production in 
a dose-dependent manner (Fig. 6A and 6B).
Figure 4: Effect of HS-133 on cell cycle in SkBr3 cells. (A) SkBr3 cells were treated with HS-133 (1–50 μM) for 24 h, stained 
with propidium iodide (PI) and analyzed on a FACScalibur flow cytometer. (B) Quantification of the PI staining data was presented as the 
percentages of cell cycle distribution. (C) Western blotting of cell cycle-related proteins.
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Figure 5: Effect of HS-133 on apoptosis in SkBr3 cells. (A) The expression of the PARP, pro-caspase-9, cleaved caspase-8, cleaved 
caspase-3, and Bax were assayed by Western blotting in cells treated with HS-133 at the indicated doses for 72 h. (B) TUNEL assay in 
SkBr3 cells treated with or without HS-133 (50 μM). Cells treated with HS-133 at the indicated doses for 24 h.
To examine the effect of HS-133 on angiogenesis, 
a capillary tube formation assay using human umbilical 
vein endothelial cells (HUVECs) was performed. HS-133 
inhibited the formation of vessel-like structures, characterized 
by elongation and alignment of the cells at the indicated 
concentrations (Fig. 6C). Cell migration is critical for the 
endothelial cells to form blood vessels during angiogenesis, 
and is necessary for tumor growth and metastasis. Thus, we 
conducted a wound migration assay to study the effect of 
HS-133 on cell migration. When the endothelial cell layer 
was wounded and incubated in a medium containing 1, 5, or 
10 μM HS-133 for 18 h, the cell migration was significantly 
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Figure 6: Effect of HS-133 on angiogenesis of SkBr3 cells and HUVECs. (A) Expression of HIF-1α and VEGF by HS-133 
in hypoxia-induced SkBr3 cells. The cells were treated with various concentrations of HS-133 (1–50 μM) under hypoxic mimicking 
conditions induced by a treatment with 100 μM CoCl2 for 16 h. (B) Production of VEGF by HS-133 in hypoxia-induced SkBr3 cells for 
24 h. Statistical significance of differences between each treatment group and the control (**, p < 0.01) or CoCl2 alone (
##, p < 0.01) was 
determined. Effects of HS-133 on tube formation (C) and migration assay (D) in HUVECs. To evaluate inhibitory effect of HS-133 on 
tube formation of HUVECs, the cells were treated with HS-133 of the indicated dose for 20 h. Wound migration assay was determined at 
indicated doses for 18 h. Statistical significance of differences between HS-133 treated groups and the control (*p < 0.05,**p < 0.01) was 
determined.
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inhibited (Fig. 6D). Considering that endothelial migration 
and tube formation have all highly relevant properties of 
angiogenesis, our results illustrated that HS-133 has the 
ability to block angiogenesis.
In vivo imaging of HS-133
To evaluate whether HS-133 can be detected as 
fluorescent in the tumor, we used the SkBr3 xenograft 
model in which human breast cancer cells were 
inoculated into the dorsal flank of BALB/c nude mice. 
Fluorescence of HS-133 was obviously detected when 
HS-133 was injected intratumorally into SkBr3 tumor-
bearing mice (Fig. 7A). Tumors were excised at 1 h after 
the intratumoral injection of HS-133, frozen sectioned, 
and observed with a confocal laser scanning microscope 
after propidium iodide (PI) staining. As a result, the 
fluorescence by HS-133 became clearly visible in the 
isolated tumor (Fig. 7B).
HS-133 inhibits tumor growth
We examined the effects of HS-133 using athymic 
BALB/c nude mice implanted with the SkBr3 cells. HS-
133 was injected intratumorally 2 times per week with a 
dose of 5 mg/kg when tumors reached an average volume 
of 50–100 mm3. As a result, tumor volume and weight 
were remarkably reduced, showing an antitumor activity 
in mice treated with HS-133 (Fig. 8A and 8B). When 
HS-133 was also administered orally with a daily dose 
of 10 mg/kg for 21 days, it significantly suppressed the 
tumor growth (Fig. 8C). The average tumor volume of 
HS-133 treated mice was reduced by about 50% compared 
to that of control mice (Fig. 8D). To assess the general 
toxicity, we also measured the body weight change in 
tumor-bearing mice. The same dose of HS-133 showed no 
significant change in the body weight (data not shown), 
suggesting little toxicity of HS-133 at the tested dosage 
and conditions.
HS-133 exhibits the good oral bioavailability
Extensive preclinical pharmacokinetic evaluation 
of HS-133 in ICR mice and BALB/c nude mice bearing 
SkBr3 xenograft has been performed. The plasma 
concentration-time profile of HS-133 after oral (PO) and 
intravenous (IV) administration is shown in Fig. 9A. In 
brief, the peak plasma concentration (Cmax) of HS-133 was 
236 ng/mL occurring at approximately 4.8 h post-dose, and 
the area under the plasma concentration-time curve (AUC) 
after intravenous and oral administration were 3,410 and 
3,260 h×ng/mL, respectively. The bioavailability (F value) 
of HS-133 was 95.6%; thus, almost all molecules of 
HS-133 after oral administration were exposed to the 
systemic circulation system. Clearance (CL) and volume 
of distribution at the steady-state (Vss) after intravenous 
administration of HS-133 showed to be 1,480 mL/h/kg 
and 12,000 mL/kg, respectively. The high Vss value of 
HS-133 may indicate that HS-133 shows a rapid and high 
distribution to the tissues. Other major pharmacokinetic 
parameters are shown in Table 1.
Various tissue concentrations, such as the heart, 
lung, liver, kidney, spleen, brain, and tumor in BALB/c 
nude mice bearing SkBr3 xenograft are shown in 
Fig. 9B. The ratios of each tissue-to-plasma (KP value) 
were 3.26, 4.18, 0.11, 1.99, 3.07, 4.99, and 2.06 for 
the heart, lung, liver, kidney, spleen, brain, and tumor, 
respectively. Almost all tissues except the liver showed 
high concentration levels of HS-133 compared to the 
plasma concentration. Especially, HS-133 in the tumor 
tissue also showed high concentration level, being over 
two times the plasma concentration level. Thus, this high 
concentration level of HS-133 in tumor tissues may be 
contributed to in vivo efficacy in the SkBr3 xenograft 
model.
DISCUSSION
The PI3K/Akt pathway is one of the most frequently 
activated and deregulated pathways in various human 
cancers [6, 32, 33]. Specifically, over 70% of human 
breast cancers have a deregulated PI3K/Akt pathway [34]. 
The high frequency of PI3K/Akt pathway alterations in 
cancer has led to a surge in the development of PI3K 
inhibitors. Therapeutic targeting of the PI3K/Akt pathway 
with small molecule inhibitors may have clinical benefit, 
either as a single agent in PI3K-addicted cancers or used 
more broadly in combination with other conventional or 
targeted therapies. Several classes of inhibitors targeting 
this pathway, including both the natural and chemically 
synthesized agents, have been reported and now entered 
the clinical trials phase. Despite differences in chemical 
structures, most PI3K inhibitors competitively inhibit ATP 
binding at the catalytic site [17, 33, 35, 36]. Although the 
monitoring of intracellular drug delivery and intratumoral 
distribution can provide information for target therapy, it 
has remained difficult and proven to still be challenging. 
Radiolabeling exposes patients to ionizing radiation 
and results in imaging with poor spatial and temporal 
resolution. Optical labeling overcomes these disadvantages 
but suffers from poor tissue penetration, preventing whole-
body imaging [37]. Therefore, there is a critical need for 
noninvasive functional imaging biomarkers that confirm 
drug delivery and molecular drug activity at the tumor. In 
an effort to develop potent PI3K inhibitors, which provide 
an imageable ‘readout’, we screened a large number of 
novel fluorescent analogs of xanthine [26]. In this study, 
we describe the detailed pharmacologic characterization 
of HS-133, which revealed high potency against PI3Kα 
(0.992 μM) among them. We have shown that HS-133 
modulated PI3K/Akt signaling, elicited cell cycle arrest 
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Figure 7: In vivo imaging of HS-133. (A) Images of a fluorescent HS-133 (50 mM) in solution and the intratumoral HS-133 disposition 
in SkBr3 xenograft models using the Maestro™ In-Vivo Fluorescence Imaging System. (B) Confocal observation of tumors isolated 
1 h after the injection of vehicle or 5 mg/kg HS-133 (Blue) into SkBr3 xenograft models and observed with a confocal laser scanning 
microscope after propidium iodide (PI, Red) staining.
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regulating p27, cyclin-dependent kinase (CDK) protein 
and cyclin D1, and ultimately induced apoptosis through 
extrinsic and mitochondria-related pathways in breast 
cancer cells. Our findings are consistent with the results 
that the PI3K/Akt pathway contributes to the regulation 
of cell cycle progression, particularly at the G1/S 
transition [3, 38].
Interestingly, inhibition of the PI3K/Akt pathway 
may attack tumors by two distinct directions, by blocking 
the tumor cell growth directly and by inhibiting tumor 
angiogenesis. It is notable that the PI3K/Akt pathway 
plays an important role in the production of the key 
endothelial cell growth factor, VEGF, and in the signaling 
of the VEGF receptor [33]. HIF-1α plays a central 
role as the main regulator of the hypoxic transcription 
response [39], and VEGF is a downstream molecule of 
HIF-1α [40]. As shown in Fig. 6, HS-133 inhibited not 
only the expression of HIF-1α and VEGF under hypoxia 
induced by CoCl2 in SkBr3 cells, but also inhibited tube 
formation of and migration of the endothelial cells. 
Therefore, we suppose that HS-133 has a potential anti-
angiogenic capacity. Although HS-133 is very similar to 
the pharmacological mechanism of IPD-196, a previously 
reported PI3K inhibitor, the potency is distinctly 
different [41]. In addition, the IC50 of HS-133 was higher 
than the other PI3K inhibitor without fluorescence such 
Figure 8: Antitumor activity of HS-133 against SkBr3 xenograft. (A–B) Mice bearing subcutaneously implanted SkBr3 cells 
were intratumorally injected with HS-133 (5 mg/kg) twice a week for 19 days. (C-D) Mice bearing subcutaneously implanted SkBr3 cells 
were orally administered with HS-133 (10 mg/kg) daily for 21 days.
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as HS-104 in breast cancer [42]. Thus, we need to further 
develop the potent PI3K inhibitors with fluorescent 
function.
We also demonstrated that orally administered and 
intratumorally injected HS-133 has therapeutic efficacy 
against human breast xenografts in mice. To the best of 
our knowledge, this is the first report of an intratumorally 
injected PI3K inhibitor with antitumor activity and 
fluorescent property in vivo. Until now, only a few 
fluorescent inhibitors have been reported. For examples, 
triapine, which entered phase I and phase II clinical 
trials as a potent inhibitor of the enzyme ribonucleotide 
reductase was shown to possess intrinsic fluorescence 
properties [43]. Yenugonda et al. reported that fluorescent 
CDK inhibitors (VMY-1-101 and VMY-1-103) blocked 
the proliferation of human breast cancer cells [44]. 
Histone-deacetylase-targeted fluorescent ruthenium 
(II) polypyridyl complexes have been shown to display 
Figure 9: Plasma concentration-time profile and tissue distribution profile of HS-133 following oral (PO) administration 
or intravenous (IV) administration to mice. (A) Pharmacokinetic profile of HS-133 after PO administration or IV injection at 
5 mg/kg in ICR mice (n=5). The pharmacokinetic parameters of HS-133 are shown in Table 1. (B) Variety of tissues concentration of 
HS-133 following PO administration (10 mg/kg) to SkBr3 xenograft mice.
Oncotarget10192www.impactjournals.com/oncotarget
promising anticancer agents for the potential dual imaging 
and therapeutic application [45]. However, these studies 
only experimented in vitro without in vivo experiments. 
We investigated in vivo fluorescence imaging and detected 
the fluorescence in SkBr3 xenograft models. In addition, 
surprisingly, we observed that oral administration of 
HS-133 had a remarkably good bioavailability, and the 
high concentration level of HS-133 in tumor tissues 
may be contributed to the in vivo efficacy in the SkBr3 
xenograft model. In particular, since the level of HS-133 
was the highest in the brain tissues, it seems to have the 
potential for use in a targeted therapy for brain diseases. 
Furthermore, we observed that HS-133 is more efficient 
than other previously reported PI3K inhibitors in human 
breast cancer. For example, although the IC50 of HS-104 
(4.8 μM) was more effective by approximately 8 folds than 
HS-133 (32 μM) in SkBr3 cells, tumor growth inhibition 
was shown at the lower dose of HS-133 compared to 
HS-104 against SkBr3-bearing xenograft mice 
(respectively 10 mg/kg/d, 20 mg/kg/d) [42]. The reason 
why HS-133 showed better effect in our experiments may 
be due to good oral bioavailability. Recent studies have 
demonstrated that a number of natural products isolated 
from the plants (e.g. fruits, vegetables, spices, nuts, 
legumes, herbs, etc.) also inhibit the PI3K/Akt/mTOR 
pathway, and exhibit potent anticancer activities. As 
most of the natural products occur in our every diet day, 
and are very safe, the results suggest that those natural 
products may be explored for cancer prevention and 
treatment [36]. This special issue selects apigenin [46], 
curcumin [47], cryptotanshinone [48], fisetin [49], indoles 
(indole-3-carbinol and 3, 3-diindolylmethane) [50], 
isoflavones (genistein and deguelin) [51], quercetin [52], 
resveratrol [53], and tocotrienol [54]. Among them, 
cryptotanshinone is a potential anticancer agent. However, 
cryptotanshinone has not been in clinical trials for 
any cancer therapy because of its poor bioavailability. 
Considering the poor bioavailability of natural products, 
the good bioavailability of HS-133 can be the best 
advantage.
In conclusion, we have designed and synthesized 
HS-133, a fluorescent PI3K inhibitor with potent anti-
proliferative, pro-apoptotic capabilities, anti-angiogenic, 
and anti-tumor effects in human breast cancer. The 
intrinsic fluorescent properties of HS-133 may be proved 
to be useful by providing opportunities to study the cellular 
distribution, delivery and behavior in the biological system 
of the drugs. These findings lead us to believe that HS-133 
may represent to be a promising class of anticancer agents 
for potential dual imaging and therapeutic applications 
targeting PI3K/Akt signaling.
MATERIALS AND METHODS
Cells and materials
The human breast cancer cell lines SkBr3, T47D, 
and MCF-7, were purchased from the Korean Cell 
Line Bank (KCLB, Seoul, Korea). The SkBr3 cells 
were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM), and T47D and MCF-7 cells were cultured 
in Roswell Park Memorial Institute Media 1640 
 (RPMI-1640), supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin. FBS, cell culture 
media, penicillin-streptomycin, and all other agents used 
in cell culture studies were purchased from GIBCO 
(Grand Island, NY). Cultures were maintained at 37°C in 
a CO2 incubator with a controlled humidified atmosphere 
composed of 95% air and 5% CO2. Human umbilical 
vein endothelial cells (HUVECs) were grown in a gelatin 
coated 75 cm2 flask in a M199 medium containing 
20 ng/ml basic fibroblast growth factor (bFGF), 100 U/ml 
Table 1: Pharmacokinetics parameters of HS-133 after intravenous and oral administration at a 
dose of 5 mg/kg in ICR mice (n=5). Data represent mean ± standard deviation (S.D.).
Parameters i.v. p.o.
Tmax (h) - 4.8 ± 1.8
Cmax (ng/mL) - 236 ± 34
T
1/2, λ
 (h) 6.4 ± 0.92 6.1 ± 1.4
AUC0–24hr (h·ng/mL) 3,190 ± 288 3,000 ± 335
AUC
0-∞
 (h·ng/mL) 3,410 ± 355 3,260 ± 408
CL (mL/h/kg) 1,480 ± 157 -
Vss (mL/kg) 12,000 ± 540 -
MRT (h) 8.2 ± 0.8 9.5 ± 1.9
F (%) 95.6
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heparin and 20% FBS at 37°C. Propidium iodide (PI), 
3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT), and proteinase K were purchased from 
Sigma-Aldrich (St. Louis, MO). RNase A was purchased 
from Qiagen (Valencia, CA).
7-(3-Fluorophenyl)-1, 3-dimethyl-1H-purine-2, 
6(3H,7H)-dione
To a solution of theophylline (4.01 g, 22.2 mmol), 
3-fluorophenylboronic acid (4.04 g, 28.9 mmol), and 
copper(II) acetate (4.84 g, 26.6mmol) in dichloromethane 
(40 mL) was added pyridine (4.5 mL, 55.5 mmol), and 
the entire solution was left stirring at 40°C for 5 h. The 
solution was then filtered through a pad of celite, and 
the filtrate was concentrated under a reduced pressure. 
The filtrate was washed with dichloromethane, H2O and 
dried (MgSO4). The solvent was concentrated in vacuo 
and 7-(3-Fluorophenyl)-1, 3-dimethyl-1H-purine-2, 
6(3H,7H)-dione (44%) was purified by recrystallization 
with MeOH; 1HNMR δ(300 MHz, CDCl3); 3.51 (3H, s), 
3.62 (3H, s), 7.14 (1H, t), 7.20 (1H, t), 7.24 (1H, t), 
7.44 (1H, q), 7.82 (1H, s); 13C NMR δ (75 MHz, 
CDCl3): 28.17, 29.90, 106.99, 112.67, 115.99, 120.66, 
135.82, 141.07, 149.70, 151.41, 154.26, 160.82, 164.11; 
HRMS (EI+) m/z calcd for C13H12FN4O2[M+H]
+: 
275.0944, found: 275.0945
N-(4-(7-(3-Fluorophenyl)-1, 3-dimethyl-2, 6-dioxo-2, 3, 
6, 7-tetrahydro-1H-purin-8-yl) phenyl)acetamide
To a solution of 1, 3-dimethyl-7-N-(3-fluorophenyl)
xanthine (1.19 g, 4.3 mmol), N-(4-bromophenyl) 
acetamide (1.39 g, 6.5 mmol), copper (I) iodide (2.48 
g, 13.0 mmol) and palladium (II) acetate (291 mg, 1.3 
mmol) in DMF was added cesium carbonate (3.54 g, 
10.9 mmol) and the solution was set in a sealed tube. 
Reactions were carried out at about 140°C for 24 h under 
nitrogen purged status. The solution was filtered through 
celite to remove palladium. The filtrate was washed with 
dichloromethane, H2O and dried (MgSO4). The solvent 
was concentrated in vacuo and the residue was purified 
by flash column chromatography (CH2Cl2:MeOH, 20:1) 
to produce the desired N-(4-(7-(3-Fluorophenyl)-1, 
3-dimethyl-2, 6-dioxo-2, 3, 6, 7-tetrahydro-1H-purin-8-
yl)phenyl)acetamide (48%); 1HNMR δ(300 MHz, CDCl3): 
2.14 (3H, s), 3.43 (3H, s), 3.67 (3H, s), 7.02 (1H, m), 7.10 
(1H, d), 7.17 (1H, m), 7.37(5H, dd); 13C NMR δ (75 MHz, 
CDCl3): 24.64, 28.00, 29.88, 108.97, 115.67, 116.63, 
119.06, 123.40, 129.98, 130.51,,136.85, 139.85, 148.71, 
150.80, 151.55, 154.30, 160.76, 164.07, 168.28; HRMS 
(EI+) m/z calcd for C21H19FN5O3 [M+H] 
+: 408.1472, 
found: 408.1465.
Cell viability assay
Cell viability was performed by an MTT assay. 
Briefly, the SkBr3, T47D, and MCF-7 cells were plated 
at a density of 1-5 × 103 cells/well in a 96-well plate for 
48 h. The medium was removed, and the cells were treated 
with either DMSO as control or various concentrations of 
HS-133. The final concentration of DMSO in the medium 
was ≤ 0.1% (v/v). After the cells were incubated for 48 h, 
20 μl of MTT solutions (2 mg/ml) was added to each well 
for another 4 h at 37°C. The formazan crystals that formed 
were dissolved in DMSO (200 μl/well) via constant 
shaking for 5 min. The plate was then read on a microplate 
reader at 540 nm. Three replicate wells were used for 
each analysis. The median inhibitory concentration (IC50, 
defined as the drug concentration at which cell growth was 
inhibited by 50%) was assessed from the dose-response 
curves.
Fluorescent detection of HSS-133 by confocal 
microscopy
The SkBr3 cells were plated on18-mm cover 
glasses in DMEM medium and incubated for 24 h so that 
approximately 70% confluence was reached. The cells 
were then incubated in the presence or absence of 10 μM 
HS-133 for 4 h. After washing with phosphate buffered 
saline (PBS) three times, each slide was covered with 
DABCO (Sigma-Aldrich) and observed using a confocal 
laser scanning microscope (Olympus, Tokyo, Japan).
Western blotting
The cells were washed three times with ice-cold 
PBS before lysis, and were lysed with a buffer containing 
1% Triton X-100, 1% Nonidet P-40 (NP-40), as well as 
protease and phosphatase inhibitor cocktails (GenDEPOT, 
Barker, TX). Equal amounts of protein were separated 
by 10% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred onto the 
polyvinylidene fluoride (PVDF) membranes (Millipore, 
Bedford, MA). Immunostaining was performed 
by incubating the blots with primary antibodies, 
followed by horseradish peroxidase (HRP)-conjugated 
secondary antibody and detected with an enhanced 
chemiluminescence (ECL) plus system (Amersham 
Biosciences, Piscataway, NJ). The primary mouse 
antibodies against the following factors were used: p27 
(Cell Signaling Technologies, Danvers, MA), cyclin D1, 
hypoxia-inducible factor-1α (HIF-1α, BD Biosciences, 
SanJose, CA), VEGF (Novus Biologicals, Littleton, CO) 
and β-actin (Abcam, Cambridge, MA). The primary 
rabbit polyclonal antibodies against the following proteins 
were also used: cleaved caspase-3, poly (ADP-ribose) 
polymerase protein (PARP), p-Akt, Akt, p-mTOR, mTOR, 
p-p70S6K, p70S6K, p-4E-BP1, 4E-BP1 (Cell Signaling 
Technologies), cleaved caspase-8, procasepase-9 (Santa 
Cruz Biotechnology, Santa Cruz, CA), and α-tubulin 
(Abcam). The secondary antibodies were purchased from 
Amersham Biosciences.
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Cell cycle analysis
The SkBr3 cells were plated in 100 mm-diameter 
culture dishes. On the following day, the cells were 
treated with various concentrations of HS-133 or 0.1% 
DMSO for 24 h. The floating and adherent cells were 
collected and fixed in cold 70% ethanol at 4°C overnight. 
After washing, the cells were subsequently stained with 
50 μg/ml propidium iodide (PI) and 100 μg/ml RNase 
A for 1 h in the dark and subjected to a flow cytometric 
analysis to determine the percentage of cells at specific 
phases of the cell cycle. A flow cytometric analysis was 
performed using a FACSCalibur flow cytometer (Becton 
Dickinson, San Jose, CA) equipped with a 488 nm argon 
laser. The events were evaluated for each sample and the 
cell cycle distribution was analyzed using Cell Quest 
software (Becton Dickinson). The results were presented 
as the number of cells versus the amount of DNA, as 
indicated by the intensity of a fluorescence signal. All the 
experiments were conducted three times.
Terminal deoxynucleotidyl transferase–mediated 
nick end labeling (TUNEL) assay
The SkBr3 cells were plated on 18-mm cover 
glasses in DMEM medium and incubated for 24 h so 
that approximately 70% confluence was reached. The 
cells were then incubated in the presence or absence of 
50 μM HS-133, washed twice with PBS, and fixed in an 
acetone: methanol solution (1:1) for 10 min at -20°C. The 
stained cells were examined for a fluorescence of nuclear 
fragmentation. Terminal deoxynucleotidyl transferase–
mediated nick end labeling (TUNEL) was performed 
using the TUNEL kit (Millipore, Billerica, MA).
Tube formation assay
A 10 mg/ml (200 μl) of Matrigel (BD Biosciences) 
was polymerized for 30 min at 37°C. HUVECs were 
suspended in M199 (2% FBS) medium containing 
VEGF (50 ng/ml) at a density of 2.5 × 105 cells/ml, and 
0.2 ml of cell suspension was added to each well coated 
with Matrigel, together with or without the indicated 
concentrations of HS-133 for 20 h. The morphological 
changes of the cells and tubes formed were observed under 
a phase-contrast microscope and photographed at 200× 
and 400× magnification.
Wound migration assay
HUVECs plated on 60 mm-diameter culture dishes 
at 90% confluence, were wounded 2 mm in width with 
a sterile razor blade and marked at the injury line. After 
wounding, the peeled off cells were removed with a 
serum-free medium and further incubated in M199 with 
2% FBS, 1 mM thymidine (Sigma-Aldrich), HS-133 
(50 nM) and/or VEGF (50 ng/ml). HUVECs were allowed 
to migrate for 18 h and were rinsed with a serum-free 
medium, followed by fixing with absolute methanol and 
staining with Giemsa (Sigma-Aldrich). Migration was 
quantitated with counting the number of cells that moved 
beyond the reference line.
Enzyme-linked immunosorbent assay (ELISA)
The amount of VEGF secreted into the media was 
measured by sandwich ELISA. ELISA plates (Nunc, 
Roskilde, Denmark) were coated with 100 μl of 2 μg/ml 
anti-VEGF (R&D Systems, Minneapolis, MN) antibody 
in PBS for 24 h at 25°C. The plates were washed with 
PBS containing 0.1% Tween-20 and incubated for 1 h 
at 25°C with 200 μl/well of 1% bovine serum albumin 
(BSA, Sigma-Aldrich) in PBS. The conditioned medium 
or various concentrations of recombinant human VEGF 
were incubated for 2 h at 25°C with 100 μl of 75 ng/ml 
biotinylatedanti-VEGF antibody, and the plates were 
washed and further incubated for 30 min with 100 μl of 
HRP-conjugated streptavidin (Vector Laboratories). After 
washing, the reaction was stopped by adding 50 μl of 2 N 
H2SO4. The absorbance at 450 nm was measured with a 
96-well plate reader.
Tumor xenograft studies
To establish SkBr3 tumor xenograft in mice, the 
SkBr3 cell line was grown in a culture, detached by 
trypsinization, washed and resuspended in PBS. Six-week 
old athymic BALB/c nude mice (Central Lab. Animal 
Inc. Seoul, Korea) were injected with 5 × 106 cells in the 
right flank of each mouse to initiate tumor growth. After 
reaching a tumor volume of 50–100 mm3, mice were 
randomly divided into two groups, each having six mice. 
Mice in the control group were fed with a 0.2 mL vehicle 
(DMSO:PEG400:saline = 5:50:45) by oral gavage daily 
and the second group with 10 mg/kg dose of HS-133 in 
0.2 mL daily for 21 days. For intratumoral administration, 
HS-133 was injected intratumorally with 2 times per 
week with a dose of 5 mg/kg when tumors reached an 
average volume of 50–100 mm3. The body weight and 
tumor size were recorded twice per week. The tumor size 
was calculated by 0.5 × long axis × (short axis) 2. Animal 
care and experimental procedures were conducted in 
accordance with the Guide for Animal Experiments by the 
Korean Academy of Medical Sciences, and the protocols 
used to this study were approved by the Institutional 
Animal Care and Use Committee in Inha University 
Hospital (Approval No. 110802-105).
In vivo imaging study
Six-week old athymic BALB/c nude mice (Central 
Lab. Animal Inc. Seoul, Korea) were injected with 5 × 106 
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SkBr3 cells in the right flank of each mouse to initiate tumor 
growth. HS-133 was injected via an intratumoral injection in 
the SkBr3 tumor bearing mice. The mice were anesthetized 
with intraperitoneal (IP) administration of ketamin/rumpun, 
then, spectral fluorescence images were obtained with the 
Maestro™ In-Vivo Fluorescence Imaging System (CRi, 
Inc., Woburn, MA). The spectral fluorescence images 
consisting of HS-133 (5 mg/kg) and autofluorescence 
spectra were then unmixed based on their spectral patterns 
using commercial software (Maestro software, CRi).
Pharmacokinetic study in mouse
Eight-week old ICR mice (23–25 g) were orally 
given a 5 mg/kg dose of HS-133 in DMSO:PEG400:saline 
= 5:50:45. Blood samples (approximately 0.15 mL) were 
collected from each mouse (n = 3 mice per time point) by 
a retro-orbital bleed or terminal cardiac puncture under 
isoflurane anesthesia. Blood samples were collected in 
tubes containing K2-EDTA as the anticoagulant, pre-dose 
and at 0.5, 1, 2, 4, 8, and 24 h post-dose. Samples were 
centrifuged, and the plasma was collected and stored 
at -80°C until analysis. Total concentrations of HS-
133 were determined by LC-MS/MS, following plasma 
protein precipitation with acetonitrile, and injection of the 
supernatant onto the column, a Hypersil Gold C18 column 
(50 mm × 2.1 mm, 3μmparticle size; Thermo, Waltham, 
MA). The Agilent 1260 HPLC and Agilent 6460 triple 
quadrupole mass spectrometry system (Agilent Inc., 
Santa Clara, CA) were used for the LC-MS/MS assay. 
The mobile phase consisted of acetonitrile and 10 mM 
ammonium formate buffer (80:20, v/v), at a flow rate of 
0.3 mL/min. The lower and upper limits of quantitation of 
the assay were 0.005 and 10 μg/mL, respectively. The total 
run time was 1.5 min and the ionization was conducted in 
the positive ion mode.
The heart, lung, liver, kidney, brain, spleen, and 
tumor were collected at 30 min post-dose from 3 different 
animals at each time point, rinsed with ice-cold saline, 
weighed and stored at -80°C until analysis. For HS-133 
quantification, mouse tissues were homogenized with 
three times the volume of PBS. The homogenates were 
extracted by protein precipitation with acetonitrile. 
LC-MS/MS analysis was conducted as described for the 
plasma. The homogenate concentrations were converted 
to tissue concentrations for the calculations of each tissue-
to-plasma ratio.
Statistical analysis
Data are expressed as the mean ± S.D. Statistical 
analysis was performed using ANOVA and an unpaired 
Student′s t-test. A p-value of < 0.05 was considered 
statistically significant. Statistical calculations were 
performed using SPSS for Windows Version 10.0 (SPSS, 
Chicago, IL).
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